Vaxess Technologies
{{short description|Biotechnology company in Massachusetts, United States}}
{{Infobox company
| name = Vaxess Technologies Incorporated
| logo = Vaxess Technologies Logo.png
| logo_size = 220px
| caption =
| type =
| traded_as =
| genre =
| fate =
| predecessor =
| successor =
| foundation = {{Start date|2011|12|18}}
| founder =
| defunct =
| location_city = Kendall Square, Cambridge, Massachusetts
| location_country = United States
| locations =
| area_served =
| key_people =
| industry =
| products =
| services =
| revenue =
| operating_income =
| net_income =
| aum =
| assets =
| equity =
| owner =
| num_employees = 42
| parent =
| divisions =
| subsid =
| homepage = {{URL|http://www.vaxess.com/|Vaxess.com}}
| footnotes =
| intl =
}}
Vaxess Technologies, Inc. is a company started by a team of four graduate students from Harvard developing a suite of vaccines on the MIMIX sustained dermal delivery platform that combines high temperature stability, improved efficacy, and simplified delivery to improve global vaccine access.{{cite news|last=Burgstone|first=Jon|title=4 Harvard Start-ups to Watch|url=http://www.inc.com/jon-burgstone/4-harvard-startups-to-watch.html|accessdate=18 May 2012|newspaper=Inc.com|date=2012-04-25}}{{cite web|title=MIT $100K - Vaxess Technologies|url=http://mit100k.org/bpc/bpc-semi-finalists/vaxess-technologies/|publisher=Massachusetts Institute of Technology|accessdate=7 May 2012|archive-url=https://web.archive.org/web/20120512184348/http://mit100k.org/bpc/bpc-semi-finalists/vaxess-technologies/|archive-date=12 May 2012|url-status=dead|df=dmy-all}}{{cite news|last=Parrish|first=Kelsey|title=Vaxess Technologies – Michael A. Schrader Interview|url=http://www.outliermagazine.co/vaxess-technologies-michael-a-schrader/|accessdate=9 April 2014|newspaper=Outlier Magazine|date=2014-02-25}}{{cite news|last=Schiller|first=Ben|title=Designing a More Efficient, Temperature Proof Vaccine|url=https://www.fastcompany.com/3068899/designing-a-more-efficient-temperature-proof-vaccine|accessdate=5 May 2017|newspaper=FastCompany.com|date=2017-03-14}}
History
Students Michael Schrader, Livio Valenti, Kathryn Kosuda, and Patrick Ho started Vaxess in December 2011, based on a technology created by David Kaplan and Fiorenzo Omenetto.{{cite web|title=Vaxess History|url=http://www.vaxess.com/Company.html|publisher=Vaxess Technologies|accessdate=18 May 2012}}{{cite news|last=Landry|first=Lauren|title=How a Diverse Mix of Harvard Students & Tufts' Technology Can Increase the World's Vaccine Access|url=http://bostinno.com/2012/05/30/how-a-diverse-mix-of-harvard-students-tufts-technology-can-increase-the-worlds-vaccine-access/|accessdate=31 May 2012|newspaper=BostInno|date=2012-05-30}} Schrader graduated with an MBA from Harvard Business School in 2012. Valenti attended the John F. Kennedy School of Government. Kosuda had been a Harvard postdoctoral fellow in chemistry, and Patrick Ho had earned a J.D in 2012.[http://news.harvard.edu/gazette/story/2012/06/harvard-entrepreneurs-weave-silk-with-science/ "Harvard entrepreneurs weave silk with science"]. Harvard Gazette, June 4, 2012
In 2012, Vaxess was awarded $25,000 from Harvard Business School for Harvard's Business Plan Contest in the Business Ventures Track.{{cite news|title=Harvard's Next Zuckerberg?|url=http://video.msnbc.msn.com/cnbc/47479170#47479170|archive-url=https://archive.today/20130104063233/http://video.msnbc.msn.com/cnbc/47479170%2347479170|url-status=dead|archive-date=2013-01-04|accessdate=22 May 2012|newspaper=CNBC|date=2012-05-18}}{{cite news|last=Di Meglio|first=Francesca|title=B-School Highlights: May 4|url=http://www.businessweek.com/articles/2012-05-04/b-school-highlights-may-4|archive-url=https://web.archive.org/web/20120510075852/http://www.businessweek.com/articles/2012-05-04/b-school-highlights-may-4|url-status=dead|archive-date=May 10, 2012|accessdate=18 May 2012|newspaper=Bloomberg|date=2012-05-04}}{{cite news|last=Landry|first=Lauren|title=Harvard Business School's Business Plan Contest Doles Out Over $150K|url=http://bostinno.com/2012/04/25/harvard-business-schools-business-plan-contest-doles-out-over-150k/|accessdate=18 May 2012|newspaper=BostInno|date=2012-04-25}}{{cite news|title=Harvard Business School Holds 16th Annual Business Plan Contest|url=http://www.hbs.edu/news/releases/businessplancontest2012.html|accessdate=18 May 2012|newspaper=Harvard Business School|date=2012-04-25}} Vaxess Technologies was a semi-finalist for MIT's $100K Entrepreneurship Competition in the Life Sciences section.{{cite news|last=Landry|first=Lauren|title=The 30 Semi-Finalist Teams Competing in MIT $100K's Life Science, Product & Emerging Market Tracks|url=http://bostinno.com/2012/04/19/the-30-semi-finalist-teams-competing-in-mit-100ks-life-science-product-emerging-market-tracks/|accessdate=18 May 2012|newspaper=BostInno|date=2012-04-19}}{{cite web|title=MIT$100K Semi Finalists|url=http://mit100k.org/bpc/bpc-semi-finalists/|publisher=MIT|accessdate=18 May 2012}} In 2012, it won the Harvard President's Challenge in the Global Health section and was awarded $70,000.{{cite news|last=Friedman|first=Amy|title=Vaccination Company Wins President's Challenge Grand Prize|url=http://www.thecrimson.com/article/2012/6/5/presidents-challenge-grand-prize/|accessdate=6 June 2012|newspaper=The Harvard Crimson|date=2012-06-05}}{{cite web|title=President's Challenge Finalist Teams|url=http://i-lab.harvard.edu/presidents-challenge/finalists|publisher=Harvard|accessdate=18 May 2012}}{{cite news|last=Landry|first=Lauren|title=Harvard's Innovation Lab Announces the 10 Teams Competing for $100K in the President's Challenge|url=http://bostinno.com/2012/04/12/harvards-innovation-lab-announces-the-10-teams-competing-for-100k-in-the-presidents-challenge/|accessdate=18 May 2012|newspaper=BostInno|date=2012-04-12}}{{cite news|last=Moore|first=Mary|title=Startup Vaxess Technologies wins Harvard social enterprise award|url=http://www.bizjournals.com/boston/news/2012/06/04/vaxess-harvard-social-enterprise.html|accessdate=4 June 2012|newspaper=Boston Business Journal|date=2012-06-04}} The company was selected as a finalist for two 2013 MassTLC Awards, Start-Up to Watch and Innovative Technology of the Year: Healthcare/Life Sciences."[http://masstlcawards.org/2013/#post=459 MassTLC Technology Leadership Awards: 2013 Finalists] {{Webarchive|url=https://web.archive.org/web/20130926025329/http://masstlcawards.org/2013/#post=459|date=2013-09-26}}". MassTLC. Retrieved 15 August 2013
In May 2013, Vaxess received $3.75M in funding from Norwich Ventures and an undisclosed amount of money from angel investor Jeffrey Walker.{{cite news|last=Lauren|first=Landry|title=Aimed at Increasing Vaccine Access, Vaxess Raises the First Part of a $3.75M Series A|url=http://bostinno.streetwise.co/all-series/aimed-at-increasing-vaccine-access-vaxess-raises-the-first-part-of-a-3-75m-series-a/|accessdate=14 August 2013|newspaper=BostInno|date=2013-05-23}}
In August 2013, the company announced that it would be moving out of Harvard's Innovation Lab to a new location at LabCentral in Cambridge.{{cite web|title=Twitter Moves to LabCentral|url=https://twitter.com/Vaxess/statuses/367397642453524480|publisher=Twitter|accessdate=13 August 2013}}{{cite web|last=Fruehauf|first=Johannes|title=First company selected for LabCentral: Vaxess|url=http://www.labcentral.org/first-company-selected-for-labcentral-vaxess/|publisher=LabCentral|accessdate=14 August 2013|archive-url=https://web.archive.org/web/20131230232943/http://www.labcentral.org/first-company-selected-for-labcentral-vaxess/|archive-date=30 December 2013|url-status=dead|df=dmy-all}}
In December 2013, the Massachusetts Life Sciences Center awarded $1.5M to local startups. Vaxess received $1M of that amount which is the most that the MLSC's Accelerator Loan Program will lend to one organization. Vaxess's CEO Michael Schrader was quoted as saying, "The $1 million Accelerator loan will enable Vaxess to grow the company’s internal R&D capabilities and deliver heat-stable vaccines to patients around the world even sooner."{{cite news|last=Borchers|first=Callum|title=Massachusetts Life Sciences Center awards $1.5 million in new loans|url=http://www.boston.com/business/innovation/blogs/inside-the-hive/2013/12/19/massachusetts-life-sciences-center-awards-million-new-loans/ZLMHjrpK2A0Ld5cfI5yV6L/blog.html|accessdate=19 December 2013|newspaper=Boston Globe|date=2013-12-19}}
In January 2014, co-founder Livio Valenti was named by Forbes's 30 Under 30 in Science & Healthcare for his work with Vaxess.{{cite web|title=2014 30 Under 30: Science & Healthcare|url=https://www.forbes.com/pictures/mkg45mjhl/livio-valenti-28/|archive-url=https://web.archive.org/web/20140109082745/http://www.forbes.com/pictures/mkg45mjhl/livio-valenti-28/|url-status=dead|archive-date=January 9, 2014|work=Forbes|accessdate=28 January 2014}}{{cite news|last=Fumagalli|first=Laura|title=Livio: dalla Bocconi a Forbes, pensando alla Cambogia|url=http://www.viasarfatti25.unibocconi.it/notizia.php?idArt=13110|accessdate=28 January 2014|newspaper=Sarfatti, 25|date=2014-01-27}}{{cite news|last1=Benedettelli|first1=Benedettelli|title=I vaccini senza frigorifero di due italiani ad Harvard|url=http://www.avvenire.it/ScienzaeTecnologia/Pagine/vaccini-senza-frigorifero.aspx|accessdate=8 July 2014|publisher=Avvenire|date=2014-07-05}}
In February 2014, Vaxess added George Siber, M.D. to their organization as the chair of their Scientific Advisory Board. Previously, Siber served as the EVP and CSO of Wyeth Vaccines. He also played a role in bringing Prevnar to market.{{cite web|title=Vaccine Industry Leader George Siber, M.d. Joins Vaxess Technologies As Chairman Of Scientific Advisory Board|url=http://www.vaxess.com/wp-content/uploads/2014/02/George-Siber-to-Chair-Vaxess-SAB-Final.pdf|publisher=Vaxess|accessdate=4 February 2014|archive-url=https://web.archive.org/web/20140223133255/http://www.vaxess.com/wp-content/uploads/2014/02/George-Siber-to-Chair-Vaxess-SAB-Final.pdf|archive-date=23 February 2014|url-status=dead|df=dmy-all}}
In April 2014, Vaxess announced that Thomas Monath, MD, and Russell Middaugh, PhD. would join the company's scientific advisory board. Monath being an expert in the field of vaccinology and Middaugh being an expert in the fields of in the fields of biophysical chemistry and pharmaceutical formulation.{{cite news|title=Thomas Monath and Russell Middaugh Join Scientific Advisory Board of Vaxess Technologies|url=http://www.fiercevaccines.com/press-releases/thomas-monath-and-russell-middaugh-join-scientific-advisory-board-vaxess-te|archive-url=https://web.archive.org/web/20140406153905/http://www.fiercevaccines.com/press-releases/thomas-monath-and-russell-middaugh-join-scientific-advisory-board-vaxess-te|url-status=usurped|archive-date=April 6, 2014|accessdate=5 April 2014|newspaper=FierceMarkets|date=2014-04-04}}
In February 2015, Verizon announced that Vaxess had won one of the $1M Verizon Powerful Answers Awards. Verizon issued approximately $6 million is prizes to 12 different organizations across 4 categories. Vaxess won first place in the Transportation category, above HopOn and Matternet.{{cite news|title=Verizon's $1M Powerful Answers Award Winners Boast Solutions with Potential to Change our World for the Better|url=http://www.prnewswire.com/news-releases/verizons-1m-powerful-answers-award-winners-boast-solutions-with-potential-to-change-our-world-for-the-better-300029638.html|accessdate=22 March 2015|publisher=PR Newswire|date=2015-01-03}}{{cite news|last1=Paul|first1=Joseph|title=Purdue graduate's technology could help stabilize vaccines|url=http://www.dailyherald.com/article/20150215/news/302159999|accessdate=22 March 2015|publisher=Daily Herald|date=2015-02-15}}
In March 2017, Vaxess announced the receipt of $6M in grants from The Bill and Melinda Gates Foundation to advance both an inactivated polio vaccine as well as a measles-rubella vaccine on the company's MIMIX platform. The grants will fund development of both the MIMIX platform as well as these two specific indications over the next two years.{{cite news|title= Vaxess Technologies Receives Grants Totaling $6 Million to Develop Microneedle Vaccines for Polio, Measles, Rubella|url=http://www.prnewswire.com/news-releases/vaxess-technologies-receives-grants-totaling-6-million-to-develop-microneedle-vaccines-for-polio-measles-rubella-300418136.html|publisher=PR Newswire|date=2017-03-06}}
In November 2022, Vaxess announced $27 million in Series B funding.{{cite web |last=Cross |first=Ryan |date=November 2, 2022 |title=Hate needles? Flu vaccines of the future could be skin patches delivered to your door. - The Boston Globe |url=https://www.bostonglobe.com/2022/11/02/business/hate-needles-flu-vaccines-future-could-be-skin-patches-delivered-your-door/ |access-date=2023-01-06 |website=BostonGlobe.com |language=en-US}}{{Cite web |last=FinSMEs |date=2022-11-03 |title=Vaxess Raises $27M in Series B Funding |url=https://www.finsmes.com/2022/11/vaxess-raises-27m-in-series-b-funding.html |access-date=2023-01-06 |website=FinSMEs |language=en-US}} In December 2022, the company announced initial phase 1 clinical trial results for its flu vaccine patch.{{Cite web |last=Taylor |first=Nick Paul |date=2022-12-20 |title=Vaxess' flu vaccine patch passes early clinical test, clearing path for further development |url=https://www.fiercepharma.com/pharma/vaxess-flu-vaccine-patch-passes-early-clinical-test-clearing-path-further-development |access-date=2023-01-06 |website=Fierce Pharma |language=en}}
In May 2024, Vaxess announced $12 million in funding and named Rachel Sha as CEO of the company.{{Cite web |last=Whooley |first=Sean |date=2024-05-22 |title=Vaccine patch maker Vaxess raises $12M, names new CEO |url=https://www.drugdeliverybusiness.com/vaxess-raises-12m-names-new-ceo/ |access-date=2025-06-20 |website=Drug Delivery Business |language=en-US}}
In May 2025, Vaxess announced $9 million in funding to advance its work in GLP-1, and .{{Cite web |last=Whooley |first=Sean |date=2025-04-09 |title=Vaxess raises $9M to support drug delivery patch, GLP-1 work |url=https://www.drugdeliverybusiness.com/vaxess-raises-9m-drug-delivery-glp1/ |access-date=2025-05-30 |website=Drug Delivery Business |language=en-US}} In June, the company presented new clinical data on the capability of its drug delivery patch to deliver semaglutide.{{Cite web |last=Whooley |first=Sean |date=2025-06-23 |title=Vaxess study highlights GLP-1 delivery with microarray patch |url=https://www.drugdeliverybusiness.com/vaxess-study-glp1-delivery-microarray-patch/ |access-date=2025-06-25 |website=Drug Delivery Business |language=en-US}}
Technology
Vaxess's business plan is based around a technology developed by Tufts University Professors Fiorenzo Omenetto and David Kaplan. The technology uses a silk-derived protein called fibroin to stabilize vaccines so that they can be shipped and stored without refrigeration, eliminating the need for the cold chain.{{cite web|title=Vaxess Technologies|url=http://i-lab.harvard.edu/presidents-challenge/finalists/vaxess-technologies|publisher=Harvard Innovation Lab|accessdate=20 May 2012}}{{cite news|last=Marinelli|first=Andrea|title=Vaxess, la startup italiana che ha conquistato Harvard|url=https://translate.google.com/translate?sl=auto&tl=en&js=n&prev=_t&hl=en&ie=UTF-8&layout=2&eotf=1&u=http%3A%2F%2Famerica24.com%2Fnews%2Fvaxess-la-startup-italiana-che-ha-conquistato-harvard|accessdate=14 June 2012|newspaper=America24|date=2012-06-13}}{{cite news|title=Winning the competition for ideas|url=http://articles.boston.com/2012-05-20/business/31779616_1_vaccines-social-impact-bonds-refrigeration|accessdate=21 May 2012|newspaper=Boston Globe|date=2012-05-20}}{{dead link|date=November 2024|bot=medic}}{{cbignore|bot=medic}} Vaxess is working with vaccine manufacturers to develop heat-stable vaccines and targeting a product launch by 2019.{{cite news|last=Cohan|first=Peter|title=Vaxess Goes To Harvard|url=https://www.forbes.com/sites/petercohan/2012/08/13/vaxess-goes-to-harvard/|accessdate=13 August 2012|newspaper=Forbes|date=2012-08-13}}
References
{{Reflist|2}}
External links
- {{official website|http://www.vaxess.com/}}
{{DEFAULTSORT:Vaxess Technologies}}
Category:2011 establishments in Massachusetts
Category:Biotechnology companies established in 2011
Category:Pharmaceutical companies of the United States
Category:Privately held companies based in Massachusetts
Category:Companies based in Cambridge, Massachusetts
Category:Biotechnology companies of the United States